Medicines: Ribociclib

Study of Ribociclib and PDR001 in HR+ Metastatic Breast Cancer

Dana-Farber Cancer Institute

ADAPT trial: Endocrine + ribociclib vs. chemotherapy in HR+/HER2- early breast cancer

Kisqali (Ribociclib): Side Effects and What to Expect

Yerbba – Breast Cancer

MONALEESA-3: Ribociclib Plus Fulvestrant in HR+ mBC

Frontline endocrine therapies and ribociclib in early stage HR+ HER2- breast cancer

NEW TREATMENT FOR ADVANCED BREAST CANCER: RIBOCICLIB

LEARN everything YOU need to KNOW about PALBOCICLIB, RIBOCICLIB and ABEMACICLIB || Dr Liz O'Riordan

Dr Liz O'Riordan

Using Ribociclib in the First-Line Setting

Ribociclib in Early Breast Cancer | NEJM

NATALEE: ribociclib + NSAI as adjuvant treatment in patients with HR+/HER2− early breast cancer

KISQALI® (ribociclib) Mechanism of Action in Metastatic Breast Cancer for Patients

Ribociclib for HR+ Advanced Breast Cancer

NATALEE and monarchE: ribociclib and abemaciclib in HR+/HER2- breast cancer

RIBECCA: ribociclib, a CDK4/6 inhibitor in ER+ breast cancer

Comment: Ribociclib for breast cancer

MONALEESA-2: ribociclib + letrozole in pts with de novo metastatic disease and late recurrence

Safety and efficacy of ribociclib and letrozole in advanced breast cancer – the MONALEESA-2 trial

Adding ribociclib to endocrine therapy shows an improvement in invasive DFS in HR+/HER2 BC patients

Breast cancer breakthrough

KPRC 2 Click2Houston

Encouraging Findings With Ribociclib in HR+ Breast Cancer

Targeted Oncology